Goldman Sachs Resumes Coverage on Valeant Pharmaceuticals (VRX) at Neutral
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Goldman Sachs reinstates coverage on Valeant Pharmaceuticals (NYSE: VRX) with a Neutral rating and $50 price target following Q1 results and the recent withdrawal of its consent solicitation to acquire Cephalon (Nasdaq: CEPH).
The firm raised 2011/2012/2013E EPS to $2.80/$3.40/$3.88 from $2.60/$3.30/$3.73.
For more ratings news on Valeant Pharmaceuticals click here and for the rating history of Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $51.88 yesterday.
The firm raised 2011/2012/2013E EPS to $2.80/$3.40/$3.88 from $2.60/$3.30/$3.73.
For more ratings news on Valeant Pharmaceuticals click here and for the rating history of Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $51.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- DA Davidson Starts Comfort Systems USA (FIX) at Buy
- BNP Paribas Exane Starts NIQ Global Intelligence Plc (NIQ) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
